Wire · opportunities
World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
A phase 3 clinical trial led by Australian researchers demonstrated that a personalized mRNA vaccine reduces melanoma recurrence or death risk by 42% compared to standard immunotherapy. The vaccine, developed by Moderna and Merck, works alongside pembrolizumab and could mark a foundational shift in cancer treatment.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 12 Oct 2026 and 26 Oct 2026.
◆ ◆ The Wire takeaway
You can leverage this breakthrough to accelerate personalised cancer therapies in skin cancer, as personalised mRNA vaccines now have proven success in reducing recurrence. Competitors in oncology drug development will need to integrate personalised treatment data or risk falling behind.
◆ Coverage
8 sources · first reported 12 Oct 2026 · latest 26 Oct 2026
◆ Related on Wire
◆ Topics